|Articles|May 17, 2016

CRF Health Launches TrialConsent

CRF Health launches Trial Consent, an electronic consent solution that integrates within an eCOA platform.

CRF Health announces the launch of TrialConsent, an electronic consent solution. It has the ability to fully integrate within an existing eCOA solution or operate as a stand-alone solution.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
September 9th 2025
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
September 9th 2025
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
September 9th 2025
How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
September 8th 2025
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
September 8th 2025

CRF Health Launches TrialConsent

Newsletter

Related Articles

Trending on Applied Clinical Trials Online

Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19

ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies

AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer

Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer

Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC